APP and Alzheimer disease: Wang and colleagues (2022) reported a BACE1-aptamer–modified tetrahedral framework nucleic acid (tFNA-Apt) and evaluated its therapeutic potential against AD using both in vitro assays and an APP-PS1 transgenic mouse model.